A streptococcal prophage lytic enzyme lys1644 and its application
By developing the streptococcal prophage lys1644, cloning and expressing antibacterial agents with broad-spectrum antibacterial effects, the problem of difficult prevention and control of mastitis and other streptococcal infections in the prior art is solved, and the streptococcal infections is achieved. Effective inhibition and treatment.
Patent Information
- Application Number
- CN202310898216.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-21
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-07-21
AI Technical Summary
The existing technology has not yet developed a broad-spectrum effective streptococcal phage lyase, which is difficult to effectively prevent and control mastitis and other streptococcal infections.
A streptococcal prophage lys1644 was developed. By cloning the amino acid sequence of the lysase and using prokaryotic expression, it induces the expression of a lysase with a broad-spectrum antibacterial effect and is used to prepare antibacterial agents.
lys1644 has significant antibacterial effects on Streptococcus aureus, Staphylococcus aureus and Staphylococcus epidermis, providing a theoretical basis for the prevention and treatment of mastitis and other bacterial infections of dairy cow. The product has low production cost and strong activity, and is suitable for promotion. application.
Smart Images

Figure CN116855486B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of streptococcal related disease prevention and treatment, and more specifically to a streptococcal prophage lytic enzyme lys1644 and an application thereof. Background Art
[0002] Streptococcus bacteria are Gram-positive bacteria, widely distributed in nature, human and animal feces, and the nasopharynx of healthy people, including a wide variety of pathogenic bacteria. Human pathogens include Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus faecalis, which can cause clinical diseases such as sepsis, arthritis, meningitis, endocarditis, encephalitis, rheumatic fever, and scarlet fever; Streptococcus dysgalactiae, Streptococcus agalactiae, and Streptococcus uberis infecting cattle can cause symptoms such as mastitis in dairy cows; Streptococcus suis can cause meningitis, sepsis, and pneumonia in pigs and humans; Streptococcus equi infection can cause equine glanders in horses, wound infections, and bacteremia in humans. Streptococcal disease has caused great harm to human health and caused huge losses to the animal husbandry industry. The emergence of antibiotics has brought streptococcal infections under certain control. However, with the irregular use of antibiotics in human medicine and animal husbandry industry, their drug resistance has gradually strengthened. The resulting multidrug-resistant bacteria have no available antibiotics to treat. Therefore, there is an urgent need to develop a new class of antimicrobial drugs or antimicrobial agents for the prevention and control of streptococcal infections.
[0003] Bacteriophages are viruses that can infect prokaryotic microorganisms such as bacteria and archaea. They can quickly lyse bacteria through the "perforin-lyase" binary system. Therefore, bacteriophages and their derived lyases can be used as alternative antibacterial agents to antibiotics. The lysis spectrum of bacteriophages is generally narrow, and their application is limited because bacteria can quickly evolve resistance to surface receptors. However, lyases derived from bacteriophages have a relatively wide lysis spectrum and can be used as an efficient and safe natural antibacterial agent for the prevention and control of drug-resistant pathogenic bacteria.
[0004] Phage lytic enzymes can be used as antimicrobial agents to specifically and rapidly kill host bacteria. Lytic enzymes act on the peptidoglycan on the surface of bacteria. Since peptidoglycan is a key component of the cell wall and is highly conserved within the species, lytic enzymes exhibit a broader spectrum of lytic activity, which also determines that it is more difficult for bacteria to develop resistance to lytic enzymes. At the same time, when lytic enzymes are used to treat animals infected with pathogenic bacteria, the host animals will produce antibodies against them, but the active center of the lytic enzyme is generally not an antigenic epitope exposed on the surface, so antibodies against the lytic enzyme will not weaken its lytic and bactericidal effect. Moreover, lytic enzymes have a synergistic antibacterial effect when used in combination with other antimicrobial agents such as antibiotics, which can not only broaden the lytic spectrum, but also more effectively exert antibacterial activity and reduce the probability of bacteria developing resistance.
[0005] At present, there is no broad-spectrum effective streptococcal phage lytic enzyme developed to prevent and control streptococcal infections related to bovine mastitis and diseases caused by other streptococci such as Streptococcus suis, Streptococcus equi, Streptococcus pneumoniae and Streptococcus pyogenes.
[0006] Therefore, how to provide a streptococcal phage lytic enzyme targeting a spectrum of streptococci is a problem that those skilled in the art need to solve urgently. Summary of the invention
[0007] In view of this, the present invention provides a streptococcal prophage lytic enzyme lys1644, which has antibacterial activity against Streptococcus dysgalactiae, Staphylococcus aureus and Staphylococcus epidermidis associated with bovine mastitis, providing a theoretical basis for the prevention and treatment of bovine mastitis and bacterial infection.
[0008] In order to achieve the above object, the present invention adopts the following technical solution:
[0009] A streptococcal prophage lytic enzyme Lys1644, the amino acid sequence of the lytic enzyme Lys1644 is shown in SEQ ID NO.1.
[0010] Preferably, the structural domain of the streptococcal prophage lytic enzyme lys1644 includes an N-terminal glucosaminidase cleavage domain, a middle CHAP cleavage domain and a C-terminal SH3-5 binding domain.
[0011] Preferably, the N-terminal glucosaminidase cleavage domain is from amino acid 2 to amino acid 145, the middle CHAP cleavage domain is from amino acid 163 to amino acid 296, and the C-terminal SH3-5 domain is from amino acid 322 to amino acid 390.
[0012] As an inventive concept identical to the above technical solution, the present invention also requests protection for the use of the streptococcal prophage lytic enzyme lys1644 in the preparation of relevant drugs for lysing Streptococcus dysgalactiae, Staphylococcus aureus or Staphylococcus epidermidis.
[0013] As an inventive concept identical to the above technical solution, the present invention also seeks to protect the use of Streptococcus prophage lytic enzyme lys1644 in the preparation of antibacterial agents for treating bovine mastitis and other bacterial infections.
[0014] As an inventive concept identical to the above technical solution, the present invention also requests protection for the use of a gene encoding the amino acid sequence shown in SEQ ID NO.1 in the preparation of drugs related to the lysis of Streptococcus dysgalactiae, Staphylococcus aureus or Staphylococcus epidermidis.
[0015] Preferably, the nucleotide sequence of the gene is shown as SEQ ID NO.2.
[0016] As an inventive concept identical to the above technical solution, the present invention also requests protection for a specific primer for amplifying the gene encoding the above-mentioned streptococcal prophage lytic enzyme lys1644, which are lys1644-F and lys1644-R, as shown in SEQ ID NO.3~SEQ ID NO.4, respectively.
[0017] A drug comprises streptococcal prophage lytic enzyme lys1644, wherein the amino acid sequence of the lytic enzyme lys1644 is shown in SEQ ID NO.1, and the use concentration of the streptococcal prophage lytic enzyme lys1644 is 50 μg / mL.
[0018] As an inventive concept identical to the above-mentioned technical scheme, the present invention also requests protection for the use of the streptococcal prophage lytic enzyme lys1644 in the preparation of a biological material for lysing Streptococcus dysgalactiae, Staphylococcus aureus or Staphylococcus epidermidis, wherein the biological material comprises a recombinant expression vector and a recombinant engineered bacterium; the recombinant expression vector is formed by recombination of an expression vector and a coding gene as shown in SEQ ID NO.2; the recombinant engineered bacterium is formed by transforming the recombinant expression vector into a host Escherichia coli.
[0019] The present invention also provides a method for preparing streptococcal prophage lytic enzyme lys1644, the specific steps of which are as follows:
[0020] (1) Using the genome of Streptococcus dysgalactiae SD24 as a template, amplify the nucleotide sequence of the prophage lytic enzyme lys1644;
[0021] (2) cloning the nucleotide sequence obtained in step (1) into an expression vector to obtain a recombinant expression vector;
[0022] (3) transforming the recombinant expression vector obtained in step (2) into competent Escherichia coli cells to obtain recombinant engineered bacteria;
[0023] (4) Using recombinant engineered bacteria to induce expression of the lytic enzyme lys1644;
[0024] (5) Extract and purify the lysase Lys1644 obtained in step (4).
[0025] Preferably, the enzyme digestion method used in the cloning process of the lysine lys1644 nucleotide sequence is double digestion with Bam HI and Kpn I.
[0026] Preferably, the expression vector is pEC, with a 6xHis tag at the C-terminus; a T7 lac promoter, and a Ni +Affinity chromatography purification. The vector can also be selected from other vectors suitable for expressing foreign genes in E. coli, such as pET series, pGEX series, pMAL series or pBAD series.
[0027] Preferably, the engineering bacteria is Escherichia coli BL21 (DE3), and may also be an expression host bacteria such as Escherichia coli Rosseta.
[0028] Preferably, the inducing agent used to induce expression is IPTG, the induction concentration is 0.5 mmol / L, and the induction time is 16 h.
[0029] Preferably, the culture temperature of the engineered bacteria is 37°C and the induction expression temperature is 25°C.
[0030] It can be seen from the above technical solution that compared with the prior art, the present invention clones the prophage lytic enzyme Lys1644 from the genome of Streptococcus dysgalactiae SD24, and adopts prokaryotic expression to induce the expression of soluble lytic enzyme. The lytic enzyme Lys1644 has a broad-spectrum antibacterial effect on Streptococcus dysgalactiae, Staphylococcus aureus or Staphylococcus epidermidis, laying the foundation for the prevention and treatment of diseases infected by the above bacteria. The present invention can obtain a large number of products with clear enzyme activity and physicochemical properties, with low product production cost and strong product activity, which can meet the production needs of popularization and application. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0032] Figure 1 The attached figure is a SDS-PAGE result diagram of prokaryotic expression and purification of lysase protein lys1644; wherein M is a standard protein molecular weight marker; 1 is the whole protein of the engineering strain transformed with an empty vector; 2 is the whole protein of the recombinant engineering strain transformed with a recombinant expression plasmid; 3 and 4 are the purification results of lysase protein lys1644;
[0033] Figure 2 The attached figure is a schematic diagram of the protein sequence structure of the lysase lys1644; wherein, Glucosaminidase is the first cleavage domain, CHAP is the second cleavage domain, and SH3-5 is the binding domain;
[0034] Figure 3 The attached figure is a diagram of the three-dimensional structure of Streptococcus prophage lytic enzyme lys644 predicted by AlphaFold;
[0035] Figure 4 The accompanying drawings are diagrams showing the in vitro antibacterial effects of different concentrations of lytic enzyme lys1644 on Streptococcus dysgalactiae;
[0036] Figure 5 The accompanying drawing is a diagram showing the pH stability test results of the lysase lys1644;
[0037] Figure 6 The attached figure is a graph showing the temperature stability of the lytic enzyme lys1644. DETAILED DESCRIPTION
[0038] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0039] Example 1 Genome sequence amplification and recovery
[0040] The whole genome of Streptococcus dysgalactiae SD24 isolated from milk samples of cows with mastitis was sequenced, the prophage genome in the genome was located through bioinformatics analysis, and the full-length nucleotide sequence of the lytic enzyme lys1644 was retrieved from the prophage.
[0041] The nucleotide sequence shown in Seq ID NO. 2 was amplified using primer pair lys1644-F / R.
[0042] Upstream primer lys1644-F: 5 , - aggagatataccatgggatcc atgacctttttagataacat-3 , , as shown in SEQ ID NO.3.
[0043] Downstream primer lys1644-R: 5 , - aaaatacaggttttcggtacc atttaatttaccccaaagac-3 , , as shown in SEQ ID NO.4.
[0044] The primer sequence contains the homology arm fragment at the expression vector connection site, and the underlined part is the homology fragment.
[0045] The reaction system is shown in Table 1.
[0046] Table 1 PCR amplification system
[0047]
[0048] Reaction conditions:
[0049]
[0050] After amplification, the PCR amplification product was checked by 1% agarose gel electrophoresis, and the target fragment amplified by PCR was recovered using the Norwegian gel recovery kit.
[0051] Example 2 Connection of recombinant expression plasmid and transformation of competent cells
[0052] 1) The expression vector was double-digested with enzymes. The enzyme digestion system is shown in Table 2.
[0053] Table 2 Enzyme digestion system
[0054]
[0055] The enzyme digestion process was as follows: 37°C, water bath for 4 h. The enzyme digestion system was verified by 1% agarose gel electrophoresis, and the gel was recovered to obtain a vector with sticky ends.
[0056] According to the target gene PCR gel recovery product and the plasmid concentration after enzyme digestion, the 20 μL one-step cloning and ligation system was determined, as shown in Table 3.
[0057] Table 3 Connection system
[0058]
[0059] 2) Mix the ligation system in Table 3 and ligate at 37°C for 30 minutes. Add 10 μL of the ligation product to 100 μL of E. coli DH5α competent cells, mix gently, and place on ice for 30 minutes. Then heat shock at 42°C for 90 seconds and quickly place on ice for 2 minutes. Add 890 μL of LB medium and culture at 37°C with shaking for 1 hour. After centrifugation at 5000 rpm for 5 minutes, discard 900 μL of supernatant, use the remaining 100 μL of resuspended bacterial solution, and evenly spread it on solid LB medium containing Kan (final concentration 50 μg / mL), and culture it inverted in a 37°C incubator overnight.
[0060] 3) Pick a single colony on the Kan plate and inoculate it into LB liquid medium containing Kan for cultivation. After obtaining a bacterial suspension, identify the positive bacterial suspension by PCR. At the same time, send the PCR identification system to Shanghai Sangon Biotech Co., Ltd. for sequencing, and compare the sequencing results with the target gene sequence. After the recombinant DH5α strain with correct sequencing is cultured overnight, the recombinant plasmid is extracted using the Novozymes plasmid extraction kit.
[0061] 4) Take 10 μL of recombinant plasmid and add it to 100 μL of E. coli BL21 competent cells, mix well and place on ice for 30 minutes. Then heat shock at 42℃ for 90 seconds and quickly place on ice for 2 minutes. Add 890 μL of LB medium and culture at 37℃ with shaking for 1 hour. Take 100 μL of bacterial solution and evenly spread it on solid LB medium containing Kan (final concentration 50 μg / mL), and culture it upside down in a 37℃ incubator overnight.
[0062] Example 3 Prokaryotic expression and purification of lysase protein lys1644
[0063] Pick a single colony on the Kan plate and inoculate it into LB liquid medium containing Kan for cultivation. After obtaining a bacterial suspension, identify the positive bacterial suspension by PCR. Transfer the positive bacterial suspension to LB liquid medium and culture at 37℃ with shaking until OD 600 After about 0.6-0.8, add IPTG with a final concentration of 0.5mmol / L, shake at 25℃ overnight to induce expression. Use the expression engineering bacteria transferred with empty plasmid as negative control. After the recombinant engineering bacteria are expanded and induced to express, use ultrasonic disruption to lyse the bacteria. After centrifugation at 12000rpm and 4℃ for 10min, take the supernatant for SDS-PAGE electrophoresis analysis. The results are as follows Figure 1 As shown, compared with the empty plasmid engineered bacteria (lane 1), the recombinant engineered bacteria showed thicker bands at 45 KDa and 30 KDa (lane 2).
[0064] The cells were resuspended in 50 mM imidazole solution, lysed by ultrasonication, and the supernatant was taken and purified by Ni + The affinity chromatography column is used to purify the lytic enzyme protein. The column is equilibrated with the equilibrium solution for 2-3 times, and then the supernatant is loaded onto the column multiple times to allow the target protein to interact with the affinity chromatography Ni. + The filler was fully combined and washed 6 times with 50mM imidazole to remove the impurities. Then 200mM imidazole was used to elute the target protein. The results of protein purification are shown in Figure 1 Lanes 3 and 4. The amino acid sequence of the purified lysate protein lys1644 is shown in SEQ ID NO.1, and the encoding gene is shown in SEQ ID NO.2.
[0065] MTFLDNIKQGCLDGWAKYKILPSLTAAQAILESGWGKHAPHNALFGIKADSSWAGKSFNTKTQEEYQPGVMTDIVDRFRAYDSWTDSIFDHGKFLNDNPRYQAVVGETDYKKACHAIKDAGYATASGYAELLIQLIEENDLQKWDDEAIGGKEKQMISSQCREVIEFFINLANAGMGVDKDNFAGWQCADVPCYAAKHWFGVDLWGNAIDLLDSAAAAGWEVHRMPTDANPRAGAFFVQSVPYHQFGHTGIVIEDSDGYTMRTIEQNIDGNADALYVGAPARFNTRDFTGVIGWFYPPYQGDAVTQTVSTEPQTSDTIVETPKSGTFTLDVAEINIRRWPSLASEVVGSYKQGDTVGFDSEGYANGYYWISYVGGSGKRNYLAIGQTDKDGNRISLWGKLN, as shown in SEQ ID NO.1.
[0066] atgacctttt tagataacat taagcaagc tgcttagacg gttgggctaa atacaaaatattgccatcct tgaccgcagc acaagcaatc ttagagagcg ggtggggtaa acatgcaccg cacaacgctgtttggaat taaggcagat agctcttgg caggcaagctc atttacact attacact aggagtatcagccaggggtt atgactgaca tagtagatag gtttagagct tatgacagct ggactgacag tattttgatcacggcaaat ttttaaacga taatccacgg tatcaggctg ttgttggtga gactgactat aaaaaagcttgtcacgctat caaggacgca ggttatgcca cggcagccg ttcacctc aactaatcgaggaaaatgac ctacaaaaat gggatgacga agctatcggt ggaaaggaga agcaaatgat tagttctcaatgtcgagaag ttattgaatt ttttataaat ttggcaaatg ctggtatggg tgttgataaa gataattttgcgggctggca atgtgcagatt gtgccgc ggggtggacc tttggggcaatgcgattgat ttgctagata gcgctgctgc cgctggttgg gaagtccacc gcatgccgac agatgcaaatccacgggctg gagcattttt tgtccaatcg gtgccatatc accaatttgg acatacggga attgtcattgaggacagc cattgatggc aatgcagatg ccttatatgtaggcgcaccagctcgtttta acactcgtga ttttactggc gttattggtt ggttttaccc accatatcaaggagatgcag tcacacaaaccgtcagcaca gagccgcaaa cgtctgacac catcgtagag acaccaaaatctggtacctt tacgctcgat gttgcagaga ttaatattag acgttggcca agcctcgcca gcgaagtagtaggcagctac aagcaaggcg atactgtcgg ctttgacagc gaaggttatg ccaatggcta ctactggattagctatgtcg gcggctctgg gaaacgcaac tatttagcta ttggtcagac tgataaagac ggaaatcgtatcagtctttg gggtaaatta aat, as shown in SEQ ID NO.2.
[0067] Example 4: Lysase lys1644 structure prediction
[0068] The amino acid sequence of lysase lys1644 (SEQ ID NO. 1) was submitted to the Pfam online server (http: / / pfam.xfam.org / ) for prediction of its domain structure. Figure 2 shown by Figure 2 It can be seen that glucosaminidase is the first cleavage domain, CHAP is the second cleavage domain, and SH3-5 is the binding domain; glucosaminidase starts at the value 2 and ends at the value 145 in the protein sequence; CHAP starts at the value 163 and ends at the value 296 in the protein sequence; SH3-5 starts at the value 322 and ends at the value 390 in the protein sequence.
[0069] The three-dimensional structure prediction of Streptococcus prophage lytic enzyme lys1644 was performed using the AlphaFold Colab website (https: / / colab.research.google.com / github / sokrypton / ColabFold / blob / main / AlphaFold2.ipynb#scrollTo=AzIKiDiCaHAn), and its amino acid sequence (SEQ ID NO.1) was submitted. After downloading the prediction results, the domain structure was drawn using pymol software. The results are shown in the figure. Figure 3 shown.
[0070] Example 5 Analysis of physicochemical properties of lysase lys1644
[0071] Number of amino acids: 401, relative molecular mass: 44336.26, theoretical pI: 4.82, amino acid type, quantity and proportion are: Ala (A) 40 10.0%, Arg (R) 13 3.2%, Asn (N) 19 4.7%, Asp (D) 33 8.2%, Cys (C) 5 1.2%, Gln (Q) 18 4.5%, Glu (E) 19 4.7%, Gly (G) 40 10.0%, His (H) 8 2.0%, Ile (I) 25 6.2%, Leu (L) 21 5.2%, Lys (K) 21 5.2%, Met (M) 6 1.5%, Phe (F) 184.5%, Pro (P) 143.5%, Ser (S) 23 5.7%, Thr ( (T) 24 6.0%, Trp (W) 13 3.2%, Tyr (Y) 19 4.7%, Val (V) 22 5.5%, Pyl (O) 0 0.0%, Sec (U) 0 0.0%, (B) 0 0.0%, (Z) 0 0.0%, (X) 0 0.0%, total number of negatively charged residues (Asp + Glu): 52, total number of positively charged residues (Arg + Lys): 34; atomic composition: C is 1987; H is 2969; N is 527; O is 609; S is 11, molecular formula: C 1987 H 2969 N 527 O 609 S 11 The total number of atoms is 6103, and the extinction coefficient is 100060. -1 cm -1 Units, measured in water at 280nm; absorbance: 0.1% (=1 g / l) 2.257; the N-terminus of the protein sequence is methionine (Met); the estimated half-life is: 30 hours (mammalian reticulocytes, in vitro).>20 hours (yeast, in vivo).>10 hours (Escherichia coli, in vivo); instability index: the instability index (II) is calculated to be 38.01, which indicates that the protein classification is stable; the aliphatic index is: 70.62, and the overall average hydrophilicity (GRAVY) is: -0.390.
[0072] Example 6 Determination of in vitro antibacterial activity and antibacterial spectrum of lysase Lys1644
[0073] Streptococci were cultured in BHI medium until the logarithmic phase. After centrifugation, the precipitate was washed twice with Tris-HCl (pH 7.5). The bacteria were then resuspended with Tris-HCl and the OD was adjusted. 600 100 μL of concentrated bacterial solution was mixed with 100 μL of lysase lys1644 at different concentrations (0, 50, 100, 150, 200 μg / mL) in a 96-well plate to adjust the OD of the mixture to 0.6. 600 The value was about 0.6, and the final concentrations of the lytic enzyme were 0, 25, 50, 75, and 100 μg / mL. 100 μL of concentrated bacterial solution and 100 μL of Tris-HCl mixed solution were used as controls. Three parallels were placed in a multifunctional microplate reader and cultured at 37°C. The OD was measured every 10 minutes. 600 Numerical value, plotting OD 600 A curve that changes over time.
[0074] The results are as follows Figure 4 As shown, the OD of the groups treated with different concentrations of lysase lys1644 600 The value showed a gradual downward trend, the bacterial solution gradually became clear, and the OD without adding lysing enzyme 600 The values were basically unchanged. Among them, the downward trend of the 25μg / mL lyase group was slightly worse; when the lyase concentration was greater than 50μg / mL, OD 600 The decrease in values tends to be consistent, indicating that the application concentration of 50μg / mL can achieve the best antibacterial effect.
[0075] Commercially available Streptococcus dysgalactiae, Staphylococcus aureus, and Staphylococcus epidermidis were used for the cleavage spectrum determination of the lytic enzyme lys1644. The strains to be tested were cultured at 37°C until the mid-logarithmic growth period, and the bacterial solution was centrifuged and the precipitate was washed twice with Tris-HCl (pH 7.5), and then the bacteria were resuspended with Tris-HCl and the OD was adjusted. 600 100 μL of concentrated bacterial solution was mixed with 100 μL of lysase lys1644 at 100 μg / mL in a 96-well plate to adjust the OD of the mixture to 0.6. 600 The value was about 0.6, the final concentration of the lytic enzyme was 50 μg / mL, 100 μL of concentrated bacterial solution and 100 μL of Tris-HCl mixed solution were used as controls, 3 parallels per group were placed in a multifunctional microplate reader and cultured at 37°C. OD was measured at 0h and 1h 600 Numerical value, calculate OD 600 The value decreases in proportion to OD 600 >20% indicated that cleavage was possible, so as to determine the cleavage spectrum of the cleavage enzyme Lys1644.
[0076] The lysis spectrum results are shown in Table 4. The lytic enzyme LYS1644 has a strong specific lysis effect on the three strains of Streptococcus dysgalactiae. In addition, the lytic enzyme also has a certain lysis effect on Staphylococcus aureus and Staphylococcus epidermidis. The results show that the lytic enzyme LYS1644 has a relatively specific antibacterial ability against Streptococcus dysgalactiae within the genus Streptococcus.
[0077] Table 4. Cleavage results of cleavage spectrum of lysase lys1644
[0078]
[0079] Example 7 Identification of pH and temperature stability of lysase lys1644
[0080] pH stability analysis of lysase lys1644: Streptococcus was cultured in BHI medium to the logarithmic phase, and the bacterial suspension was divided into 8 groups. After centrifugation, the precipitate was washed twice with different pH buffers (50mM NaCl, 50mM Na2HPO4, pH adjusted to 4, 5, 6, 7, 8, 9, 10, 11, respectively), and then the bacteria were resuspended with the corresponding pH buffer and the OD was adjusted. 600 In a 96-well plate, 100 μL of concentrated bacterial solution at different pH conditions was mixed with 100 μL of 1ys1644 (100 μg / mL lysate) at the same pH (lysate was prepared by diluting Tris-HCl at different pH values) to adjust the OD of the mixture to 0.6. 600 The value is about 0.6, and the final concentration of the lyase is 50 μg / mL. After mixing, quickly place it in an ELISA reader to measure the initial A 630 Then, the mixture of bacteria and lytic enzymes under different pH conditions was incubated at 37°C, and the final A was measured after 1 h. 630 Value, and calculate △A 630 100 μL of concentrated bacterial solution and 100 μL of Tris-HCl mixed solution were used as controls, with 3 parallels in each group.
[0081] The results of the test are as follows Figure 5 As shown, the lyase lys1644 has a △A value of 6 under the condition of pH value. 630 The highest value has the highest lytic activity, and the lytic enzyme activity decreases to varying degrees with the increase or decrease of pH value.
[0082] Temperature stability analysis of lysase lys1644: Streptococci were cultured in BHI medium until the logarithmic phase. After centrifugation, the precipitate was washed twice with Tris-HCl (pH 7.5), and then the cells were resuspended with Tris-HCl and the OD was adjusted. 600The volume was about 0.6, and then concentrated to 1 / 2 of the original volume. The concentrated bacterial solution was placed at 4°C, 25°C, 37°C, 42°C, and 56°C for 30 min. At the same time, the lysase lys1644 to be added was treated in the same way at the corresponding temperature. 100 μL of concentrated bacterial solution was mixed with 100 μg / mL of lysase 1ys1644 in a 96-well plate to make the OD of the mixed solution 600 The value is about 0.6, and the final concentration of the lyase is 50 μg / mL. After mixing, quickly place it in an ELISA reader to measure the initial A 630 Then the mixture of bacteria and lytic enzyme was placed under different temperature conditions for incubation, and A was measured after 1 hour. 630 Final value and calculate △A 630 100 μL of concentrated bacterial solution and 100 μL of Tris-HCl mixed solution were used as controls, with 3 parallels in each group.
[0083] The results of the test are as follows Figure 6 As shown, the lysase lys1644 at 37°C △A 630 The highest value was obtained, indicating the highest cleavage activity. The cleavage activity decreased to varying degrees with increasing or decreasing temperature. Under all the measured temperature conditions, the cleavage enzyme lys1644 maintained a high cleavage activity and had good temperature stability.
[0084] In summary, the optimal enzyme activity conditions for lys1644 are pH=6, 37℃, and lys1644 has good temperature stability.
[0085] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.
[0086] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A streptococcal prophage lytic enzyme lys1644, characterized in that The amino acid sequence of the lysase lys1644 is shown in SEQ ID NO.
1.
2. Use of the streptococcal prophage lytic enzyme lys1644 according to claim 1 in the preparation of related drugs for lysing Streptococcus dysgalactiae, Staphylococcus aureus or Staphylococcus epidermidis.
3. Use of the streptococcal prophage lytic enzyme lys1644 according to claim 1 in the preparation of a biomaterial for lysing Streptococcus dysgalactiae, Staphylococcus aureus or Staphylococcus epidermidis, wherein the biomaterial comprises a recombinant expression vector and a recombinant engineered bacterium; the recombinant expression vector is formed by recombining the expression vector and the SEQ ID NO.2 sequence; the recombinant engineered bacterium is formed by transforming the recombinant expression vector into a host Escherichia coli.
Citation Information
Patent Citations
Production method for streptococcus specific bacteriophage lyase
CN101275146A
Streptococcus pyogenes antigens
CN102512670A
Streptococcus prophage lyase lys733 and application thereof
CN116355887A
Preparation of phage cocktail as therapeutic agent for cow mastitis and use thereof
US20220347241A1
